Sentences with phrase «leading vaccine researcher»

But another leading vaccine researcher, who declined to be named, disagrees.

Not exact matches

«If they could figure out a way to streamline, it would be a lot better,» said Kim Janda, a professor of chemistry at the Scripps Research Institute in La Jolla, California, who leads a team of researchers developing a vaccine that would prevent fentanyl overdoses by keeping the drug from reaching the brain.

Researchers have new insights into how protective antibodies attack dengue viruses, which could lead to more effective dengue fever vaccines and drug therapies.

Yoshihiro Kawaoka of the University of Wisconsin - Madison, lead researcher on the other study, adds that the meeting allowed him and Fouchier to explain their work, including the potential benefits for surveillance of emerging flu strains (Nature 481, 417 - 418; 2012) and for vaccine preparation (Nature 482, 142 - 143; 2012).

Johns Hopkins Bloomberg School of Public Health researchers say a new candidate vaccine against respiratory syncytial virus (RSV) made with a weakened version of the virus shows great promise at fighting the disease, the leading cause of hospitalization for children under the age of one in the U.S.

In Britain, in 1991, researchers led by Jim Stott at the National Institute of Biological Standards and Control in north London, stunned their colleagues by announcing that they had apparently protected monkeys from infection with the monkey virus SIV — the simian equivalent of HIV — with a vaccine based simply on human T cells.

To test the nasal vaccine in adults, researchers at 13 hospitals nationwide, led by Kristin Nichol of the Veterans Affairs Medical Center in Minneapolis, gave it to more than 2800 people in fall 1997; 1400 others got a placebo.

The researchers, led by Ram Sasisekharan, the Alfred H. Caspary Professor of Biological Engineering at MIT, also found that current flu vaccines might not offer protection against these strains.

In these countries pneumonia, malaria and diarrhea were the leading causes of death), so to improve survival in these regions the researchers recommended improving the uptake of breastfeeding, providing vaccines for pneumonia, malaria and diarrhea, and improving water and sanitation.

These findings could lead to the first broadly effective ebolavirus therapies and vaccines, say researchers.

Researchers led by a team at Duke University identified these immunologic variations by studying blood samples collected from people living with HIV by the NIAID - supported Center for HIV / AIDS Vaccine Immunology (CHAVI).

A study led by Johns Hopkins Bloomberg School of Public Health researchers found that injecting a vaccine - like compound into mice was effective in protecting them from malaria.

Another study, led by researchers at NIAID, to be presented at the vaccine conference this week analysed the molecular structure of antibodies from the blood of vaccinated people and found that some of their antibodies recognized the same amino acids in the V2 region.

To better understand why women who initiate HPV vaccination do not complete the series, a team of researchers led by Dr. Abbey Berenson from the University of Texas Medical Branch examined the correlates of vaccine series completion among young women using data from the Behavioral Risk Factor Surveillance System (BRFSS), a cross-sectional telephone health survey conducted by the Centers for Disease Control and Prevention.

Although no vaccine against HIV exists, advances in prevention and treatment have led to a growing conviction among researchers, public health officials, and politicians that the HIV / AIDS epidemic can be brought to a halt with existing tools.

Thanks to its resemblance to the smallpox virus, researchers were able to use vaccinia as a vaccine for the disease, eventually leading to its eradication in the late 1970s.

Led by University of Texas Austin researcher Dr Steve Bellan, and in collaboration with the U.S. Centers for Disease Control and Prevention (CDC), the study on the design of CDC's vaccine trial in Sierra Leone is published in The Lancet Infectious Diseases.

Only one vaccine has been licensed, and neither it nor any others in development today will be 100 percent effective against malaria infection, said lead researcher José A. Stoute, associate professor of medicine and microbiology and immunology.

That's what the lead researcher of a study of a breast cancer vaccine in mice would like you to think.

The reports build on findings some years ago from Emory Vaccine Center researchers led by Rafi Ahmed.

New details of the structure of the human papillomavirus (HPV) may lead to better vaccines and HPV anti-viral medications, according to research led by a Penn State College of Medicine researcher.

«If you don't treat it, within 20 to 40 days visceral leishmaniasis very often kills the victim,» said Alexandre Marques, a professor in the parasitology department of the Universidade Federal de Minas Gerais in Brazil, and one of the lead researchers on the new experimental vaccine.

An international team led by researchers at the Broad Institute of MIT and Harvard, the Harvard T.H. Chan School of Public Health and Fred Hutchinson Cancer Research Center uncovered the influence of genetic variation on vaccine effectiveness after applying cutting - edge DNA sequencing technology to almost 5,000 patient blood samples.

The finding «can color how we approach future vaccine discovery and development,» said Broad senior associate member Dr. Dyann Wirth, a top malaria researcher at Harvard who led the study along with Fred Hutch biostatistician Dr. Peter Gilbert.

A team of U.S. government researchers led by scientists from the Walter Reed Institute of Research (WRAIR) created a dual vaccine formulated with three main components: a segment of a protein expressed on the surface of HIV; a synthetic molecule that resembles heroin and its degradation products; and a potent adjuvant to stimulate the immune system.

Every day, our researchers work towards making discoveries that will lead to better preventions, therapies, and ultimately cures for immune system - related diseases, as well as working for ways to improve the vaccines that the world so desperately needs.

Researchers, led by Dr Gregory Poland and Dr Richard Kennedy from the Mayo Clinic, set out to examine how differences in an individual's immune cells correlate to their response to the seasonal flu vaccine.

A team of scientists led by NAC and IAVI researchers have already engineered a prototype immunogen — the active ingredient of a vaccine — based on insights gleaned from such studies.

Many leading researchers and specialists now believe that several of the vaccines that we routinely give to dogs and cats have a greater duration of immunity than had previously been thought.

Further investigating led researchers to estimate the prevalence of vaccine - induced sarcomas to be as much as one cat in 1,000, or up to 22,000 new cases of sarcoma a year.

Few people have as intimate a knowledge of canine parvovirus as Dr. Ronald D. Schultz, Chair of the Department of Pathobiological Sciences at the University of Wisconsin - Madison, head of the Maddie's Laboratory, and one of the country's leading veterinary vaccine researchers.

Dr. Ron Schultz, our leading veterinary vaccine researcher does not recommend the use of Lyme disease vaccines on his own dogs despite living in a Lyme endemic part of the country in Wisconsin.